vs
Side-by-side financial comparison of IRIDEX CORP (IRIX) and LivaNova PLC (LIVN). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $14.7M, roughly 24.5× IRIDEX CORP). On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs -69.7%). Over the past eight quarters, IRIDEX CORP's revenue compounded faster (11.9% CAGR vs 10.6%).
IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
IRIX vs LIVN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.7M | $360.9M |
| Net Profit | — | $30.9M |
| Gross Margin | 37.2% | 65.2% |
| Operating Margin | — | 11.8% |
| Net Margin | — | 8.6% |
| Revenue YoY | -69.7% | 12.1% |
| Net Profit YoY | — | -44.7% |
| EPS (diluted) | — | $0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $14.7M | $360.9M | ||
| Q3 25 | $12.5M | $357.8M | ||
| Q2 25 | $13.6M | $352.5M | ||
| Q1 25 | $11.9M | $316.9M | ||
| Q4 24 | $12.7M | $321.8M | ||
| Q3 24 | $11.6M | $318.1M | ||
| Q2 24 | $12.6M | $318.6M | ||
| Q1 24 | $11.8M | $294.9M |
| Q4 25 | — | $30.9M | ||
| Q3 25 | $-1.6M | $26.8M | ||
| Q2 25 | $-994.0K | $27.2M | ||
| Q1 25 | $-1.7M | $-327.3M | ||
| Q4 24 | $-834.0K | $55.9M | ||
| Q3 24 | $-1.9M | $33.0M | ||
| Q2 24 | $-2.7M | $16.3M | ||
| Q1 24 | $-3.5M | $-41.9M |
| Q4 25 | 37.2% | 65.2% | ||
| Q3 25 | 32.1% | 68.4% | ||
| Q2 25 | 34.5% | 67.8% | ||
| Q1 25 | 42.5% | 69.7% | ||
| Q4 24 | 44.0% | 68.2% | ||
| Q3 24 | 37.3% | 70.8% | ||
| Q2 24 | 40.7% | 68.7% | ||
| Q1 24 | 37.9% | 70.3% |
| Q4 25 | — | 11.8% | ||
| Q3 25 | -11.3% | 15.1% | ||
| Q2 25 | -6.9% | 15.4% | ||
| Q1 25 | -1.7% | 15.3% | ||
| Q4 24 | -3.9% | 11.5% | ||
| Q3 24 | -16.1% | 11.2% | ||
| Q2 24 | -20.9% | 12.6% | ||
| Q1 24 | -28.0% | 5.5% |
| Q4 25 | — | 8.6% | ||
| Q3 25 | -12.6% | 7.5% | ||
| Q2 25 | -7.3% | 7.7% | ||
| Q1 25 | -14.2% | -103.3% | ||
| Q4 24 | -6.6% | 17.4% | ||
| Q3 24 | -16.7% | 10.4% | ||
| Q2 24 | -21.2% | 5.1% | ||
| Q1 24 | -29.5% | -14.2% |
| Q4 25 | — | $0.57 | ||
| Q3 25 | $-0.09 | $0.49 | ||
| Q2 25 | $-0.06 | $0.50 | ||
| Q1 25 | $-0.10 | $-6.01 | ||
| Q4 24 | $-0.05 | $1.04 | ||
| Q3 24 | $-0.12 | $0.60 | ||
| Q2 24 | $-0.16 | $0.30 | ||
| Q1 24 | $-0.21 | $-0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.0M | $635.6M |
| Total DebtLower is stronger | — | $376.1M |
| Stockholders' EquityBook value | — | $1.2B |
| Total Assets | $29.2M | $2.6B |
| Debt / EquityLower = less leverage | — | 0.31× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.0M | $635.6M | ||
| Q3 25 | $5.6M | $646.1M | ||
| Q2 25 | $6.8M | $593.6M | ||
| Q1 25 | $7.2M | $738.4M | ||
| Q4 24 | $2.4M | $428.9M | ||
| Q3 24 | $3.9M | $346.4M | ||
| Q2 24 | $4.1M | $329.2M | ||
| Q1 24 | $5.4M | $309.2M |
| Q4 25 | — | $376.1M | ||
| Q3 25 | — | $434.5M | ||
| Q2 25 | — | $430.6M | ||
| Q1 25 | — | $628.2M | ||
| Q4 24 | $1.0M | $627.0M | ||
| Q3 24 | $1.4M | $625.5M | ||
| Q2 24 | — | $624.5M | ||
| Q1 24 | — | $623.8M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | $4.7M | $1.2B | ||
| Q2 25 | $6.1M | $1.1B | ||
| Q1 25 | $852.0K | $1.0B | ||
| Q4 24 | $2.1M | $1.3B | ||
| Q3 24 | $2.6M | $1.3B | ||
| Q2 24 | $4.2M | $1.2B | ||
| Q1 24 | $6.5M | $1.2B |
| Q4 25 | $29.2M | $2.6B | ||
| Q3 25 | $28.4M | $2.6B | ||
| Q2 25 | $31.6M | $2.5B | ||
| Q1 25 | $34.2M | $2.6B | ||
| Q4 24 | $29.1M | $2.5B | ||
| Q3 24 | $30.2M | $2.5B | ||
| Q2 24 | $31.2M | $2.5B | ||
| Q1 24 | $34.1M | $2.5B |
| Q4 25 | — | 0.31× | ||
| Q3 25 | — | 0.38× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 0.61× | ||
| Q4 24 | 0.48× | 0.47× | ||
| Q3 24 | 0.53× | 0.48× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $82.4M |
| Free Cash FlowOCF − Capex | — | $50.2M |
| FCF MarginFCF / Revenue | — | 13.9% |
| Capex IntensityCapex / Revenue | — | 8.9% |
| Cash ConversionOCF / Net Profit | — | 2.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | $173.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $82.4M | ||
| Q3 25 | $-1.2M | $85.1M | ||
| Q2 25 | $-397.0K | $62.9M | ||
| Q1 25 | $-1.1M | $24.0M | ||
| Q4 24 | $-1.2M | $78.7M | ||
| Q3 24 | $-3.1M | $51.0M | ||
| Q2 24 | $-1.3M | $43.4M | ||
| Q1 24 | $-1.6M | $10.0M |
| Q4 25 | — | $50.2M | ||
| Q3 25 | $-1.2M | $62.2M | ||
| Q2 25 | $-410.0K | $47.8M | ||
| Q1 25 | $-1.2M | $13.2M | ||
| Q4 24 | $-1.2M | $68.3M | ||
| Q3 24 | $-3.1M | $32.8M | ||
| Q2 24 | — | $31.2M | ||
| Q1 24 | $-1.7M | $3.6M |
| Q4 25 | — | 13.9% | ||
| Q3 25 | -9.4% | 17.4% | ||
| Q2 25 | -3.0% | 13.6% | ||
| Q1 25 | -9.8% | 4.2% | ||
| Q4 24 | -9.8% | 21.2% | ||
| Q3 24 | -26.5% | 10.3% | ||
| Q2 24 | — | 9.8% | ||
| Q1 24 | -14.0% | 1.2% |
| Q4 25 | — | 8.9% | ||
| Q3 25 | 0.1% | 6.4% | ||
| Q2 25 | 0.1% | 4.3% | ||
| Q1 25 | 0.1% | 3.4% | ||
| Q4 24 | 0.1% | 3.2% | ||
| Q3 24 | 0.0% | 5.7% | ||
| Q2 24 | 0.0% | 3.8% | ||
| Q1 24 | 0.0% | 2.2% |
| Q4 25 | — | 2.67× | ||
| Q3 25 | — | 3.18× | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.41× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 2.65× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRIX
Segment breakdown not available.
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
